The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: (link sends e-mail)

Study Name on (link is external)
Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients
Study DrugQR-010
Type of Study DrugCFTR Modulation
Study TitlePhase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, 
Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis
Study Phase1b
Study SponsorProQR Therapeutics

Link on (link is external) (link is external)

Participating ECFS-CTN sitesPlease contact for most recent sitelist
Age18 Years to 60 Years